STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug

Eli Lilly's next-generation obesity drug, retatrutide, demonstrated significant weight loss and blood sugar reduction in a study, but new data revealed seven cases of arrhythmias and three major cardiovascular complications among 403 participants. The findings were presented at the American Diabetes Association meeting and published in the Lancet.